Lamivudine and Tenofovir Disoproxil Fumarate
Brand Names: Cimduo
Methodology & AI Transparency ⓘ
Lamivudine and Tenofovir Disoproxil Fumarate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage cimduo: ® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.
- 2 Real-world patient consensus: Zero-PHI community consensus: 80% favorable across 18 logged regimens (Cimduo).
- 3 Typical cash cost range: Public pharmacy ledger: $17.97 low cash benchmark vs. $44.03 chain retail average ($0.2339/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Lamivudine and Tenofovir Disoproxil Fumarate tolerability events: headache (8.5%), diarrhea (7.2%), cutaneous rash (5.4%).
Ask our AI Specialists anything about Lamivudine and Tenofovir Disoproxil Fumarate
Lamivudine and Tenofovir Disoproxil Fumarate Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage cimduo: ® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. CIMDUO is a two-drug combination of lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.
12.1 Mechanism of Action CIMDUO is a fixed-dose combination of antiviral drugs 3TC and TDF with antiviral activity against HIV-1 . Mechanism of Action Lamivudine 3TC is a synthetic nucleoside analogue with activity against HIV-1 and HBV. Intracellularly, 3TC is phosphorylated to its active 5’‑triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC‑TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. Tenofovir Disoproxil Fumarate TDF is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate.
Following administration (300 mg/1 / 300 mg/1 Tablet, Film Coated), Lamivudine and Tenofovir Disoproxil Fumarate achieves ~86% systemic bioavailability (Lamivudine and Tenofovir Disoproxil Fumarate) bioavailability and maximum serum exposure occurs 2–3 hours after lamivudine and tenofovir disoproxil fumarate dosing onset, governed by a Steady-state plasma equilibrium reached over 3–13 hour t½ intervals for Lamivudine and Tenofovir Disoproxil Fumarate terminal half-life through predominantly hepatic biotransformation with renal elimination of polar lamivudine and tenofovir disoproxil fumarate conjugates.
Before initiating Lamivudine and Tenofovir Disoproxil Fumarate at 300 mg/1 / 300 mg/1 Tablet, Film Coated, clinical safety checklists rule out 4 contraindications cimduo is contraindicated in patients with a previous hypersensitivity reaction to any of the components contained in the formulation.; cimduo is contraindicated in patients with previous hypersensitivity to any of the components of this product.. Logged tolerability patterns center on headache (8.5% of reports), nausea (7.9% of reports), diarrhea (7.2% of reports).
Azole antifungals or ritonavir can markedly raise Lamivudine and Tenofovir Disoproxil Fumarate plasma peaks; dose reduction may be warranted.
Reconcile eGFR-adjusted medications before escalating Lamivudine and Tenofovir Disoproxil Fumarate in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS CIMDUO is contraindicated in patients with a previous hypersensitivity reaction to any of the components contained in the formulation.
- CIMDUO is contraindicated in patients with previous hypersensitivity to any of the components of this product.
Logged Side-Effect Incidence (18 Reports)
Lamivudine and Tenofovir Disoproxil Fumarate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lamivudine and Tenofovir Disoproxil Fumarate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Treatment staying on track with medication on efficacy of dolutegravir plus Methods: staying on track with medication was estimated using pill counts and categorized as ≥90% vs Results: In each. HIV research & clinical practice • 2021-12-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34913844 ↗ |
| Can This Approach Help? Inside the Latest Research on Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Of 734 participants randomized, 728 received study drugs and were included in analyses. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33336698 ↗ |
| New Insights on Population how the body absorbs the medicine modeling of dolutegravir/lamivudine: What a 362-Participant Study Found No dose adjustments are recommended based on these analyses. Antimicrobial agents and chemotherapy • 2024-05-02 • Phase III Randomized Trial | N = 362 | 87/100 | PMID 38587380 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of dolutegravir/lamivudine in virologically suppressed female Results confirm the robustness of DTG/3TC as a switch option in virologically suppressed females with HIV-1, with outcomes similar to those in males. HIV medicine • 2024-07-15 • Phase III Randomized Trial | N = 133 | 82/100 | PMID 38760011 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive This analysis provides new information about DTG/3TC treatment for people with HIV-1 and isolated reactive anti-HBc. HIV medicine • 2026-07-15 • Phase III Randomized Trial | N = 44 | 82/100 | PMID 41992416 ↗ |
Lamivudine and Tenofovir Disoproxil Fumarate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2339/unit (~$7.02/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $44.03 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $17.97 / mo | View logs ↓ |
Lamivudine and Tenofovir Disoproxil Fumarate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lamivudine and Tenofovir Disoproxil Fumarate RxNorm Concept ID | 2003249 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2339 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $44.03 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $17.97 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lamivudine and Tenofovir Disoproxil Fumarate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Lamivudine and Tenofovir Disoproxil Fumarate integrating DailyMed SPL (2021-02-15), CMS NADAC ($0.2339/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lamivudine and Tenofovir Disoproxil Fumarate community threads and patient logs by age, biological sex, dosage, and treatment duration.